SG11201701728PA - A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells - Google Patents

A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

Info

Publication number
SG11201701728PA
SG11201701728PA SG11201701728PA SG11201701728PA SG11201701728PA SG 11201701728P A SG11201701728P A SG 11201701728PA SG 11201701728P A SG11201701728P A SG 11201701728PA SG 11201701728P A SG11201701728P A SG 11201701728PA SG 11201701728P A SG11201701728P A SG 11201701728PA
Authority
SG
Singapore
Prior art keywords
cells
generation
stem cell
cancer stem
antigen specific
Prior art date
Application number
SG11201701728PA
Inventor
Shu Wang
Chunxiao Wu
Jieming Zeng
Yovita Ida Purwanti
Andrew Khoo
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201701728PA priority Critical patent/SG11201701728PA/en
Publication of SG11201701728PA publication Critical patent/SG11201701728PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/45—Artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201701728PA 2014-09-04 2015-09-04 A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells SG11201701728PA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201701728PA SG11201701728PA (en) 2014-09-04 2015-09-04 A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201405497U 2014-09-04
SG11201701728PA SG11201701728PA (en) 2014-09-04 2015-09-04 A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
PCT/SG2015/050301 WO2016036319A1 (en) 2014-09-04 2015-09-04 A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

Publications (1)

Publication Number Publication Date
SG11201701728PA true SG11201701728PA (en) 2017-04-27

Family

ID=55440201

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701728PA SG11201701728PA (en) 2014-09-04 2015-09-04 A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

Country Status (5)

Country Link
US (1) US20170191034A1 (en)
EP (1) EP3189133A4 (en)
CN (1) CN107148470A (en)
SG (1) SG11201701728PA (en)
WO (1) WO2016036319A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137691B (en) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 Antibodies specific for human T-cell immunoglobulin and ITIM domain (TIGIT)
US20190345447A1 (en) * 2016-09-29 2019-11-14 Hadasit Medical Research Services And Development Ltd. Dendritic cell preparations, compositions thereof and methods of using same
CN113440606A (en) * 2021-06-02 2021-09-28 深圳市罗湖区人民医院 Specific pluripotent stem cell tumor vaccine and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2630968A1 (en) * 2006-06-30 2013-08-28 Baylor Research Institute Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
AU2008207945A1 (en) * 2007-01-22 2008-07-31 Macrogenics West, Inc. Human cancer stem cells
JP2011529080A (en) * 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド Therapies targeting cancer stem cells
KR20130080444A (en) * 2010-05-25 2013-07-12 도쿠리츠교세이호진 고쿠리츠간켄큐센터 Induced malignant stem cells or pre-induction cancer stem cells capable of self-replication outside of an organism, production method for same, and practical application for same
CN102793912A (en) * 2011-05-26 2012-11-28 北京清美联创干细胞科技有限公司 Dendritic cell (DC) tumor vaccine and preparation method thereof
CN104080907A (en) * 2011-11-30 2014-10-01 日本国立癌症研究中心 Induced malignant stem cells
EP2885403A4 (en) * 2012-08-15 2016-04-13 Neostem Oncology Llc Rapid method production high purity cancer stem cells and population of high purity cancer stem cells
WO2014066615A1 (en) * 2012-10-24 2014-05-01 The Regents Of The University Of Michigan Cancer stem cell vaccination and treatment
EP2968407A4 (en) * 2013-03-13 2017-01-04 Neostem Oncology, LLC Individualized high purity colon carcinoma stem cells, methods and use of the same

Also Published As

Publication number Publication date
EP3189133A1 (en) 2017-07-12
CN107148470A (en) 2017-09-08
WO2016036319A1 (en) 2016-03-10
US20170191034A1 (en) 2017-07-06
EP3189133A4 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
IL290459A (en) Cs1 targeted chimeric antigen receptor-modified t cells
HK1246342A1 (en) METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
EP3131653A4 (en) Improved precipitation process for producing perovskite-based solar cells
EP3152412A4 (en) Dispatchable solar hybrid power plant
EP3302548A4 (en) Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
ZA201606867B (en) Bonds for solar cell metallization
EP3171897A4 (en) Biopolymer-nanoparticle composite implant for tumor cell tracking
EP3161854A4 (en) Techniques for forming a compacted array of functional cells
EP3164893A4 (en) A method for forming a photovoltaic cell and a photovoltaic cell formed according to the method
ZA201508420B (en) Hybrid energy plant
EP3094976A4 (en) Cell surface prostate cancer antigen for diagnosis
PL3138903T3 (en) Cells for producing human antibody
EP3177711A4 (en) Use of ligands for the programmed cell death receptor conjugated to solid supports for the expansion of human regulatory t cells
SG11201701728PA (en) A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
EP3103870A4 (en) Method for obtaining transformed cells of plant
EP3146545A4 (en) Electrode for a photovoltaic battery
SG11201705095VA (en) Process for the manufacture of solar cells
EP3145899A4 (en) Fuel production using solar energy
GB201703277D0 (en) Three-dimensional solar cells
AU2015101860A4 (en) For solar cell of similar particle accelerator architecture
IL243491A0 (en) Methods for large scale generation of stem cells
AU2014900910A0 (en) Improved precipitation process for producing perovskite-based solar cells
AU2014903494A0 (en) Hybrid Solar Collector
AU2014902594A0 (en) Hybrid Solar Collector
GB201415537D0 (en) Renewable battery energy generation